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Tuberculosis (TB) remains a major cause of morbidity 
and mortality worldwide and the main cause of death in 
correctional facilities in middle- and low-income coun-
tries. Due to the closed environment and the concentra-
tion of individuals with TB-related risk factors, effective 
measures are required to control TB in such settings. 
Isoniazid preventive therapy (IPT) represents an effec-
tive and cost-effective measure. Despite international 
recommendations that IPT be integral to TB control, it 
is seldom deployed. A systematic review of interventions 
used to assess IPT initiation and completion in correc-
tional facilities was conducted using published studies 
from two biomedical databases and relevant keywords. 
Additional references were reviewed, resulting in 18 eli-
gible studies. Most (72%) studies were conducted in the 
United States and in jail settings (60%), with the main 
objective of improving completion rates inside the facil-
ity or after release. Studies that provided data about ini-
tiation and completion rates showed poor success in cor-
rectional facilities. Adverse consequences and treatment 
interruption ranged from 1% to 55% (median 5%) in 
reported studies; hepatotoxicity was the most prevalent 
adverse reaction. Despite its accelerating effect on the de-
velopment of active TB, information on human immuno-
deficiency virus (HIV) status was provided in only half 
of the studies. Among the four studies where IPT effec-
tiveness was assessed, the results mirror those described 
in community settings. Future studies require thorough 
assessments of IPT initiation and completion rates and 
adverse effects, particularly in low- and middle-income 
countries and where comorbid viral hepatitis may con-
tribute significantly to outcomes, and in settings where 
TB and HIV are more endemic.
K E Y  W O R D S :  tuberculosis; prisons; jails; isoniazid; 
prevention
WITH NEARLY 2 billion people infected world-
wide,1 tuberculosis (TB) remains a major global public 
health problem, contributing signifi cantly to morbid-
ity and mortality. In 2009, the World Health Organi-
zation (WHO) estimated that there were 9.4 million 
incident TB cases globally. Nearly 85% of these cases 
were in the Asia and Africa regions and 11–13% of 
TB incident cases were co-infected with the human 
immunodefi ciency virus (HIV). TB mortality that 
same year resulted in 1.68 million deaths.2 
The problems associated with TB are magnifi ed in 
correctional facilities. It is estimated that TB preva-
lence within correctional facilities is up to 100 times 
higher than in the general community.3 Increased TB 
rates in correctional settings are attributable in large 
part to the high concentration of TB risk factors 
among incoming prisoners, including HIV infection, a 
history of substance use disorders, low socio-economic 
status, malnutrition, homelessness, previous con-
tainment in closed settings and inability to access 
community-based health care.4,5 Additional contrib-
uting risk factors, such as poor ventilation, over-
crowding and the recycling of individuals through 
the correctional setting, facilitate transmission of TB in 
these settings, including multidrug-resistant strains.4,5 
Staggering incarceration rates globally have resulted 
in more than 10 million people being imprisoned,6 
including 400 000 detained annually in compulsory 
drug detention centers.7 These settings serve as im-
portant reservoirs of infection, resulting in TB trans-
mission into the community after release and through 
prison staff.3,8,9 Studies from the United States con-
fi rm this dynamic, demonstrating that approximately 
40% of all persons diagnosed with TB disease annu-
ally in the United States had passed through a correc-
tional facility.10
Although alternatives to incarceration are preferred, 
correctional settings do serve as potentially important 
and feasible settings for screening high-risk, diffi cult-
to-access populations for active TB disease, latent 
TB infection (LTBI) and other infectious diseases.11 
From a public health perspective, these facilities are 
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increasingly recognized as being important sites for 
TB prevention and control efforts.12
LTBI is one of the most prevalent infections among 
inmates in correctional facilities, including prisons, 
jails and detention centers.13 Within long-term facili-
ties or those that house a large proportion of individ-
uals with HIV infection, LTBI may have suffi cient time 
to progress into active TB disease (with a 10% life-
time risk for immunocompetent subjects compared 
to a 10% annual risk for HIV-infected persons14), with 
resultant transmission to other inmates and staff.13,14 
In prisons where many prisoners are malnourished, 
the lifetime risk of progressing to TB disease is even 
higher.3 
Prevention of active TB among those with LTBI is 
effective, safe and inexpensive. Isoniazid preventive 
treatment (IPT), confi rmed in two meta-analyses, is 
effective at preventing progression to active TB dis-
ease in 60% of non-HIV-infected and 36% of HIV-
infected populations.15,16 Recent WHO guidance for 
resource-constrained settings recommends that IPT 
be administered to all HIV-infected persons, irrespec-
tive of tuberculin skin test (TST) reactivity;17 how-
ever, clinical trials suggests that it is more effective 
among those with positive TST results.15,16
Although isoniazid (INH) is well-tolerated, drug-
related hepatotoxicity occurs in 1–2% of cases. The 
frequency of hepatotoxicity is negligible among those 
aged ⩽35 years, and increases with age, alcohol con-
sumption and among Asian men. Analyses of IPT 
studies confi rm that benefi ts outweigh the risks, even 
among elderly persons,18,19 and have resulted in rec-
ommendations to offer IPT to all persons with posi-
tive TST, irrespective of age.20
Despite these general recommendations and the 
unique characteristics and dynamics of correctional 
inmates compared to those in community settings, 
IPT is seldom provided in closed settings (prisons, 
jails and detention centers). Reasons for the lack of 
implementation of IPT have included concerns about 
lack of effectiveness, adherence, safety and cost of 
IPT in these settings. To address these stated reasons, 
we conducted a systematic literature review to ex-
plore published studies that were applicable to cor-
rectional facility inmates to address issues related to 
the initiation and completion of IPT either within these 
settings or after release, to provide empiric guidance 
for public policy and provide insight into future re-
search studies.
METHODS
Literature search 
A systematic review of the literature was conducted 
using PubMed and Web of Science following PRISMA 
guidelines.21,22 Key words included ‘correctional’, ‘pris-
on’, ‘jail’, ‘detention’ and ‘isoniazid’ or ‘isoniazid pre-
ventive therapy’. Articles were included if published 
from 1966 to January 2011 and written in any lan-
guage. Additional primary references from review arti-
cles and international reports were also reviewed to en-
sure completeness. The three non-English articles that 
were written in Spanish were translated using Google 
Translate; one author (FLA) is fl uent in Spanish.
Exclusion criteria
Articles involving studies of IPT that were not con-
ducted within correctional facilities, that used regi-
mens other than INH or were not clinical research 
studies (i.e., editorials, letters of correspondence, 
author’s reply and guidelines) were excluded from 
the review.
Data extraction
Eligible studies were reviewed independently by two 
authors (HAAA, FLA). Due to heterogeneity in study 
reporting, a structured data extraction form was 
created that included each of the following: 1) exact 
site and continent where the study was conducted; 
2) year of publication (categorized by decade); 3) study 
setting where the study was conducted (whether 
prison, jail or both); 4) study design (categorized as 
cross-sectional, cohort, case-control, or randomized 
controlled trial [RCT]); 5) study outcome of interest 
(whether the objective of the study was to examine 
IPT completion within the facility or after release, 
impact on TB incidence or IPT safety); 6) whether or 
not HIV infection rates were described; and 7) partic-
ipants’ socio-demographic characteristics. 
In relation to the outcome of interest, extracted 
data were extended to include relevant information 
on enrollment prevalence (prevalence of inmates di-
agnosed with LTBI and/or started IPT), prevalence of 
active TB prior to starting IPT, prevalence of hepatitis 
C virus (HCV) co-infection, history of alcohol use 
prior to incarceration, liver disease among partici-
pants, duration and completion rates of IPT, reasons 
for defaulting, prevalence and types of adverse effects 
(particularly that of drug-induced hepatitis) and pre-
ventive effi cacy of the intervention (difference in TB 
development at the end of the follow-up period).
Data analysis
Extracted data were entered into a Microsoft Excel 
spreadsheet (Microsoft, Redwoods, WA, USA) for fi -
nal analysis through SPSS® version 17.0 (Statistical 
Package for the Social Sciences Inc, Chicago, IL, USA). 
Results were expressed as percentages. Descriptive sta-
tistics (mean and median) were described when data 
could be pooled.
RESULTS
Search strategy
The search strategy initially yielded 43 undupli-
cated studies (Figure); 16 were subsequently excluded 
IPT  in  correctional  facilities 873
because they did not involve IPT (e.g., multidrug re-
sistance in prisons, post-release general health care to 
inmates and TB outbreak investigation in prison), and 
another 11 were excluded because they did not in-
volve IPT within the correctional setting or addressed 
INH resistance. Five more articles were excluded be-
cause regimens other than INH were examined. As a 
result, 11 published studies remained from the initial 
search and an additional seven studies were obtained 
after secondary review of references, resulting in 
18 eligible papers for fi nal assessment.10,12,19,23–37 
The details of the 18 eligible studies are provided in 
the Table. 
Year of publication
The majority (n = 12, 67%) of the studies were pub-
lished after 2000, fi ve were published between 1990 
and 1999 and one in 1989.
Geography
The prevalence of TB differs among regions and 
countries. In general, TB prevalence is highest in sub-
Saharan Africa and South-East Asia and lowest in Eu-
rope and North America. Most of the studies (n = 
13, 72%), however, were conducted in North Ameri-
can correctional settings, all in the United States. 
Four studies were conducted in Europe—all in Spain, 
and only one study was from Singapore, a country 
not highly representative of Asia’s TB epidemic.
Study setting
Most studies (n = 11, 61%) were conducted solely in 
jail settings, while two additional studies were con-
ducted in both jail and prison settings and fi ve were 
conducted in prisons.
Study design
More than half of the studies (n = 10) were prospec-
tive cohort studies, while the remainder were either 
cross-sectional (n = 5) or RCTs (n = 3).
Primary outcome of the study
Nearly all of the studies (n = 15, 83%) examined IPT 
completion rates among inmates and interventions to 
improve them. Completion of IPT in jail (n = 4) or 
after release from jail (n = 7) was the primary objec-
tive among the reviewed studies. Two additional 
studies examined IPT completion rates in facilities 
that combined both jail and prison, while two were 
conducted solely among prison detainees. Two stud-
ies explored the impact of IPT on TB incidence inside 
prisons, and one was conducted to compare the ef-
fectiveness and completion rate of IPT using a brief, 
non-standard TB prophylaxis regimen using rifampi-
cin (RMP) plus INH for 3 months.
Demographic characteristics of participants
The age of the participants varied among the studies. 
In half of the studies, the mean age of participants 
was 30–39 years, while four studies had younger 
study populations, with mean age 20–29 years. An 
additional study included participants aged <40 years, 
while age was not mentioned in two studies. Over 
90% of study participants were men. 
HIV prevalence inside the facility
Voluntary counseling and HIV testing (VCT) was 
available in most of the correctional facilities where 
the studies were conducted. Information on HIV 
prevalence among participants (or in the facility) was 
not provided in half of the studies, while the remain-
ing nine studies showed variable HIV prevalence, 
ranging from a high of 30% in Spain to diverse prev-
alence elsewhere, including in the United States, where 
there were low VCT rates. The study from Asia pro-
vided no information about HIV. 
Prevalence of TB inside the facility (pre-intervention)
More than 60% (n = 11) of the articles did not pro-
vide information about the prevalence of active TB in 
the correctional setting before the start of the study. 
The remaining seven studies showed varying preva-
lence of active TB disease in the setting, even within 
Figure Process of search and inclusion in the final analysis. 
IPT = isoniazid preventive therapy; TB = tuberculosis.
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the same country (United States, as an example). The 
prevalence of active TB within the setting was highest 
in the study from Singapore (1.1%), and varied in the 
United States from 6.8 to 105 per 100 000 inmates. 
Enrollment and completion rates
Latent TB infection
Only half of the studies provided information on the 
prevalence of LTBI among inmates. Prevalence varied 
even among inmates within the same country. Gener-
ally, prevalence in US correctional facilities was less 
than 30% of tested inmates, while studies from Spain 
showed nearly 50% prevalence. In the Singapore 
prison, nearly 70% of inmates had LTBI.
Rate of prisoners starting IPT
Inside correctional facilities, many factors might deter 
eligible inmates from being initiated on an LTBI treat-
ment course. Fourteen studies (77%) presented data 
about the rate of enrollment of inmates with LTBI. 
Median enrollment was 57% (range 5–93) among 
the 14 studies that presented such data. Reasons for 
low enrollment included transfer to another facility 
or a short sentencing period in fi ve studies; partici-
pant refusal in three studies; age >35 years in one 
study; and previous IPT course in one study. No rea-
son was provided in the four remaining studies. 
Duration of IPT 
Trials of the duration of effective IPT in the general 
community have been conducted for 6-, 9- and 12-
month IPT courses. Of the 18 correctional studies, 
eight (44%) used the 1994 Centers for Disease Con-
trol and Prevention (CDC) recommendation of IPT 
for 6 months in HIV-negative and 12 months for 
HIV-infected persons,38 although three of these were 
conducted after publication of the 2000 joint Ameri-
can Thoracic Society (ATS) and CDC recommenda-
tions.20 Six studies used 6-month IPT, regardless of 
HIV status and four studies used 9-month IPT.20 
Completion rate
Nearly all of the studies (89%) provided data on IPT 
completion rate, irrespective of whether the treat-
ment was within the facility or given after release 
(particularly for short-term facilities such as jails). 
Median completion rate was 44%, ranging from 3% 
to 87% for the 16 studies in which data were avail-
able. One study was excluded from the rate analysis 
as only one participant was enrolled in the study and 
he completed treatment inside the facility. Reasons 
for non-completion were transfer or release from the 
facility (n = 5), loss to follow-up (n = 7), refusal to 
complete IPT (n = 6), and adverse reactions that re-
quired discontinuation of IPT (n = 9). Reported ad-
verse reactions were variable, and ranged from 1% 
to 55%. Although treatment cessation was low over-
all, hepatotoxicity was the most commonly reported 
adverse reaction leading to treatment cessation or in-
terruption. In the one study in which mortality was 
reported, four of 64 participants died (mortality 
6.25%); none of the deaths were related to IPT and 
all were HIV-infected. Two of the studies provided 
information on HCV co-infection; prevalence was 
21% among a US cohort and 71% among Spanish 
participants. Hepatotoxicity requiring treatment ces-
sation was reported in respectively 12.5% and 22.5% 
of participants in these two studies.26,29 
Effectiveness
Four (22%) studies provided data on TB incidence 
during the designated follow-up period. TB incidence 
did not differ (4.23 vs. 2.08 cases per 100 person-years 
[py]; adjusted odds ratio [aOR] 0.5, 95% confi dence 
interval [CI] 0.09–2.8) in a study in Spain comparing 
the effi cacy of 12 months of INH with 3 months of 
INH+RMP after a 19-month follow-up period. An-
other Spanish study showed that TB incidence was 
signifi cantly higher (17 vs. 1 case per 100 py) among 
those who were not given IPT than among those 
who completed ⩾6 months of IPT. An observational 
US jail study reported no TB cases among 176 in-
mates who completed a full 6-month course of IPT 
after 5 years of follow-up. Active TB did develop in 
three cases, however, resulting in an annual rate of 
108 cases per 100 000 population among those who 
initiated but did not complete IPT. Finally, the study 
from Singapore reported the development of four TB 
cases, all of whom were direct contacts of an active 
TB case and who had not started IPT due either to ele-
vated hepatic transaminases or to TST-negative status.
DISCUSSION
Despite the increased contribution of TB in criminal 
justice settings, there are few data on the utility and 
implementation of IPT. It should, however, be noted 
that there appears to be increasing interest in this is-
sue, as most of the data are reported from the past 
decade. Unfortunately, the majority of the studies 
were conducted in low TB endemic, high-income 
countries (72% of the studies were conducted in the 
United States). This divergence between where IPT 
studies were conducted and where there is the great-
est need geographically may, in part, refl ect the 
WHO recommendation to focus on increased detec-
tion and early diagnosis in low- and middle-income 
prison settings, where resources are often constrained.3 
The wisdom of such an approach may, however, be 
short-sighted, as these settings, particularly prisons, 
are highly structured, can ensure adherence to ther-
apy (especially in long-term facilities) and shoulder a 
disproportionate burden of disease, including both 
HIV and TB. Data collected since 2000 may, in ad-
dition, need reconsideration, as the prevalence of 
HIV in these settings appears to have been increasing 
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over the past decade since the recommendations were 
made.6,39 
Jails, or short-term detention facilities, may be less 
than ideal for routine implementation of IPT unless 
inmates have at least 9 months remaining on their 
sentence. They are, however, important sites not only 
for identifying individuals at increased risk for infec-
tious diseases, including IPT-eligible persons, but also 
for initiating and continually engaging individuals 
from the community who are already on treatment.11 
Most reported TB outbreaks occurred in prisons, re-
inforcing the importance of IPT in longer-term facili-
ties.40 In addition, periods of incarceration inside pre-
adjudication facilities (e.g., jails, pre-trial detention, 
etc.) are usually unpredictable, as most detainees 
leave within a relatively short time period and a de-
tainee’s status changes frequently.11 Short incarcera-
tion periods in such facilities might represent a chal-
lenge for IPT implementation in terms of enrollment 
and completion rates, although data are emerging for 
the creation of interventions that effectively link 
treatment from the criminal justice system with com-
munities.11,41 In the present review, 11 of 18 studies 
were conducted in jails, and all sought to improve 
IPT completion during incarceration and/or facilitate 
it after release. In four studies from the United States, 
although completion rates were low (30%, 33% and 
39%) during jail detention, they were even lower 
(17%) when patients were followed up after release. 
As there is considerable overlap between individuals 
with TB and substance use disorders,42 emerging data 
suggest that treatment outcomes of infectious dis-
eases after release are optimized when the substance 
use disorder is treated simultaneously, including the 
use of medication-assisted therapies.43,44
Post-release interventions to improve IPT comple-
tion have had variable results, but are somewhat dis-
appointing. Tulsky et al. reported that simple pre-
r elease education and counseling was associated with 
a low (3%) linkage to the fi rst visit to a TB clinic 
within 1 month of release.33 White et al. demonstrated 
that a single educational session delivered immediately 
prior to release from jail did not improve IPT comple-
tion (52% vs. 50% for controls),35 while other RCTs 
found that more intensive educational group sessions 
had relatively poor outcomes, but signifi cantly in-
creased (by two-fold) jail post-release IPT completion 
compared to controls (23% vs. 12%).34,36,37 Overall, 
completion rates were relatively low, but the added 
contribution of a fi nancial incentive did not apprecia-
bly improve IPT completion compared to controls 
(12% vs. 12%). 
To address these dismal outcomes, studies were 
conducted to examine the impact of a short, but rec-
ognized LTBI treatment regimen (2 months of RMP+ 
pyrazinamide, 2RZ) on completion rates within jail 
settings. Lincoln et al. found that compared to 6 or 
12 months of IPT, short-course treatment was signifi -
cantly more successful in completing LTBI prophylaxis 
(88% vs. 74%) and was equally well-tolerated.26 In 
another prospective US jail study, the 2RZ regimen 
was well-tolerated and, compared to standard IPT, 
resulted in a four-fold increase in the numbers of in-
mates who completed LTBI treatment. Tolerability 
was high, with only 8% of participants discontinuing 
treatment due to adverse side effects.45 
Another study that included jail inmates and 
homeless persons in three US cities examined adverse 
events and treatment completion rates using the 2RZ 
treatment regimen. Completion rates of respectively 
47.5% and 43.6% among jail inmates and homeless 
persons were reported, suggesting that medically 
marginalized individuals in jails were equally likely 
(or unlikely) to complete the regimen, and that jail 
detention per se did not adversely affect completion 
rates. Overall, 13.4% of subjects who discontinued 
their treatment did so due to adverse effects. Hepato-
toxicity was the cause of drug cessation in 6% of the 
participants, and there was one death due to liver 
failure. Increasing age, abnormal baseline aspartate 
aminotransferase (AST) levels and unemployment 
within the past 24 months were independent risk fac-
tors for hepatotoxicity.46 
In 2002, the US-based CDC amended their LTBI 
treatment guidelines as a result of increased safety 
concerns about the short-course 2RZ regimen after a 
series of fatalities. The new guidance preferred the 
9-month IPT regimen, and recommended that the 2RZ 
regimen should be used with caution, and only in those 
without underlying liver disease or previous INH-
related liver injury. Moreover, subjects prescribed the 
2RZ regimen should have hepatic transaminases and 
bilirubin measured bimonthly,47 which may not be 
feasible in prisons and resource-constrained countries.
Data from an RCT of over 8000 subjects recently 
confi rmed that combined INH+rifapentine, ad-
ministered once weekly for 12 weeks, resulted in sig-
nifi cantly fewer cases of active TB observed over a 
33-month observation period (7 vs. 15), higher com-
pletion rates (82% vs. 69%), and a similar safety 
profi le compared to standard 9-month IPT.48 This ap-
proach has considerable promise for treatment in 
short-term criminal justice settings, but has yet to be 
empirically tested, especially in populations with high 
rates of viral hepatitis,49,50 where toxicity levels may 
be increased. 
Finally, Nolan et al. investigated the impact of in-
stituting an outreach program to improve inmates’ 
adherence after release from jail.30 IPT was provided 
as 900 mg twice weekly under direct observation (di-
rectly observed therapy) by an outreach worker. De-
spite the less frequent dosing, IPT completion rates 
were low (60%), albeit higher than all other studies 
reported, with an estimated modest number of TB 
cases prevented (4.4 future TB cases). As a result, they 
recommended that resources might be better directed 
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towards screening and treatment of active TB inside 
jails. A post-release cost-effectiveness analysis fol-
lowed this study arguing against avoiding IPT in jails. 
Despite the low completion rate (55%), TB screening 
and IPT treatment in jail with follow-up after release 
was cost-effective (programmatic cost = US$32 866) 
compared to the public health cost due to TB reactiva-
tion (US$42 093), particularly for motivated inmates.
The CDC subsequently set national benchmarks 
for effective IPT programs in US correctional facili-
ties. Standards include screening of all inmates for TB 
disease and LTBI, initiating IPT in at least 80% of in-
mates with LTBI, and completion rates of LTBI of at 
least 75%.12 Despite that, adherence to these recom-
mendations remains low. In this review, the median 
IPT enrollment rate of inmates diagnosed with LTBI 
was 57% and only two studies reported achieving the 
80% enrollment benchmark. Reasons cited for low 
enrollment rates were transfer between or release from 
a correctional facility, refusal, age limit (following the 
previous CDC recommendations) and previous course 
of IPT. Median IPT completion rates (44%), however, 
were even more dismal, and only one cited a comple-
tion rate exceeding the recommended 75%. 
Community-based IPT enrollment and completion 
rates are similarly low. A multisite prospective cohort 
of HIV-infected patients from 28 Italian specialty 
hospitals resulted in as few as 39% of eligible sub-
jects initiating IPT. Physician factors (mostly due to 
fear of adverse reactions), medical contra-indications 
and subject refusal were cited as the main reasons for 
low enrollment. Although 72% of those initiating 
IPT completed it, more than half of non-completers 
self-discontinued their medication, while the rest did 
so due to adverse reactions (neuropathy and elevated 
AST levels).51 A retrospective assessment of IPT from 
a TB clinic in Rhode Island confi rmed that 81.6% of 
patients initiated IPT, but only 61.7% completed the 
9-month course. The high initiation rate in this set-
ting may be due to the increased intrinsic motivation 
of individuals who followed through on a referral to 
receive services from a specialty TB clinic. The lower 
retention on IPT, however, was due to loss to poor 
follow-up (35.7%), adverse effects (2.6%), pregnancy, 
transfer to another state and death unrelated to IPT.52 
In recognizing the high default rate from IPT, Chais-
son et al. conducted an RCT to identify the optimal 
adherence strategy for completing IPT among inject-
ing drug users.53 Subjects either received directly 
o bserved preventive therapy (DOPT) twice-weekly, 
self-administered therapy with peer education and 
counseling, or routine standard of care. Each group 
was re-randomized to receive a monthly US$10 sti-
pend for optimal adherence. Although adherence was 
highest in the DOPT groups, IPT completion was 
similar for all groups, and fi nancial incentives did not 
improve either adherence or completion rates. Rea-
sons for non-completion include failure to return 
(12.3%), voluntary withdrawal (1.3%), death unre-
lated to IPT (1.6%), adverse reactions (0.6%) and 
development of active TB (0.6%).
Adverse reactions to IPT contribute signifi cantly 
to treatment non-completion, including death. INH-
induced hepatotoxicity, defi ned as hepatic transami-
nases exceeding fi ve times the upper limits of normal, 
is considered one of the most common and serious 
adverse consequences of IPT. Risks associated with 
this complication include increasing age, Asian race, 
female sex, alcohol consumption, liver disease (par-
ticularly viral hepatitis) and elevated baseline hepatic 
transaminases. The ATS recommends frequent moni-
toring of liver enzymes among those who chronically 
consume alcohol, take concomitant hepatotoxic medi-
cations, have viral hepatitis or other pre-existing liver 
disease or abnormal baseline alanine aminotransfer-
ase, and in pregnant women.20 In this review, adverse 
events were responsible for treatment cessation in a 
median of 5% of individuals, with hepatotoxicity be-
ing responsible for half of these. The one study that 
compared hepatotoxicity within a correctional facil-
ity with that of the general community was in Singa-
pore, where this adverse effect was 10 times higher 
among correctional inmates (4.8% vs. 0.45%);25 one 
explanation is that IPT is supervised within struc-
tured correctional settings, resulting in higher drug 
exposure due to improved adherence. Alternatively, 
the prevalence of viral hepatitis co-infection may have 
been higher among prisoners due to mandatory in-
carceration of drug users in many international set-
tings. Two studies further examined the increased 
risk related to INH-related hepatotoxicity, including 
two confi rming HCV infection, four confi rming alco-
hol consumption and one study reporting underlying 
liver disease (etiology not specifi ed).26 
HIV-infected patients remain the highest priority 
for screening and initiating treatment for LTBI.54 At 
the time of these studies, the WHO3 and CDC20 rec-
ommended IPT for all HIV-infected inmates with a 
positive TST (⩾5 mm), regardless of age. In this re-
view, however, only half of the studies reported infor-
mation regarding HIV infection within the facility or 
among subjects participating in the studies. New inter-
national guidelines now recommend that IPT be pro-
vided for all HIV-infected persons, irrespective of TST 
reaction or previous TB status.17 There are no data, 
however, to support the effi cacy, completion rates or 
adverse consequences of this approach in correctional 
settings in low- and middle-income countries. 
Although IPT’s effectiveness in preventing active 
TB has been documented in many geographically di-
verse global settings,15,16,26 only four studies reviewed 
here reported reductions in TB incidence after treat-
ment. Findings from within correctional facilities 
mirror results from the general community, i.e., IPT 
effectively reduces progression from LTBI to active 
TB disease among incarcerated people.
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CONCLUSION AND RECOMMENDATIONS
Despite several decades of IPT use, assessment of its 
use in correctional facilities remains limited, yet con-
tinues to highlight the importance of correctional set-
tings being ideal sentinel sites for screening and treat-
ment of active and LTBI. The review revealed a 
paucity of studies addressing IPT implementation in 
correctional facilities, necessitating further explora-
tion of the effi cacy and safety of IPT in closed set-
tings. Most of the studies of LTBI treatment have pri-
marily been conducted in high-income countries, 
particularly where TB prevalence is low. In general, 
initiation and completion rates of IPT remain low, 
particularly in jails and short-term detention centers, 
and innovative strategies are urgently needed to pro-
vide evidence for more effective approaches to ensure 
treatment initiation and retention. 
Although the review affi rmed the safety of IPT 
among inmates, it has not been suffi ciently studied in 
settings where the syndemic of HIV, TB and injection 
drug use converge within correctional settings, where 
IPT may cause greater adverse side effects due to the 
additive hepatotoxicity or peripheral neuropathy 
from concomitant prescription of antiretroviral med-
ications and/or the potential increase in hepatotoxic-
ity among those co-infected with viral hepatitis.42 
Furthermore, the effi cacy of IPT in correctional facili-
ties needs to be investigated further, particularly in 
high-burden countries, where TB transmission re-
mains unacceptably high in these settings. 
Although seemingly daunting, it remains of para-
mount public health importance to control TB with-
in correctional settings as it will have a dramatic im-
pact on community levels of TB. This is particularly 
relevant, as nearly all prisoners with LTBI return to 
their communities and thereby contribute to grow-
ing community TB epidemics, including those in-
volving multidrug-resistant and extensively drug-
r esistant strains.
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IPT  in  correctional  facilities i
Au niveau mondial, la tuberculose (TB) reste une cause 
majeure de morbidité et de mortalité et constitue la 
principale cause de décès dans les prisons des pays à re-
venus moyens ou faibles. Des mesures efficientes s’im-
posent pour lutter contre la TB dans de tels contextes en 
raison des environnements renfermés et de la concentra-
tion des individus porteurs de facteurs de risque liés à la 
TB. Le traitement préventif à l’isoniazide (IPT) repré-
sente une mesure efficiente et d’un bon rapport coût-
e fficacité. En dépit des recommandations internationales 
qui considèrent que l’IPT fait partie intégrante de la 
lutte contre la TB, celui-ci est rarement pratiqué. Une re-
vue systématique des interventions utilisées pour évaluer 
la mise en route et l’achèvement de l’IPT dans les pri-
sons a été menée sur base des études publiées dans deux 
bases de données biomédicales et avec les mots-clés corre-
spondants. Des références complémentaires ont été re-
vues, ce qui a mené à 18 études éligibles. La plupart des 
études (72%) ont été menées aux Etats-Unis et dans les 
contextes de prisons (60%), avec comme objectif prin-
cipal l’amélioration des taux d’achèvement à l’intérieur 
de la prison et après libération. Les études ayant fourni 
des données concernant les taux de mise en route et 
d’achèvement n’ont montré que des succès médiocres 
dans les services correctionnels. Les effets indésirables 
ainsi que l’interruption du traitement évoluent entre 1% 
et 55% (valeur médiane 5%) dans les études où ils sont 
signalés, et l’hépatotoxicité constitue la réaction indési-
rable la plus prévalente. En dépit de l’accélération du 
développement d’une TB active due au virus de l’im-
munodéficience humaine (VIH), l’information sur le VIH 
n’apparaît que dans la moitié seulement des études. Dans 
les quatre études où l’efficience de l’IPT a été évaluée, 
les résultats sont le miroir de ceux décrits dans les con-
textes de la collectivité. Des études ultérieures exigent 
une évaluation approfondie des taux de mise en route et 
d’achèvement de l’IPT et de ses conséquences défavo-
rables, particulièrement dans les pays à revenus faibles 
ou moyens et où l’hépatite virale peut contribuer de 
manière significative comme co-morbidité aux résultats 
ainsi que dans les contextes où la TB et le VIH sont plus 
prévalents. 
La tuberculosis (TB) sigue siendo una causa importante 
de morbilidad y mortalidad en el mundo y la principal 
causa de muerte en los establecimientos penitenciarios 
de los países de medianos y bajos recursos. En estos am-
bientes confinados que albergan una concentración de 
personas con factores de riesgo de padecer la TB, se pre-
cisan medidas eficaces de control de la enfermedad. El 
tratamiento preventivo con isoniazida (IPT) constituye 
una medida eficaz y rentable. Pese a las recomendaciones 
internacionales, rara vez se suministra este tratamiento 
preventivo. Se llevó a cabo un análisis sistemático de 
todas las intervenciones utilizadas con el fin de evaluar 
la iniciación y la compleción del IPT en los estableci-
mientos penitenciarios, a partir de dos bases de datos 
biomédicas, utilizando palabras clave pertinentes. Se ana-
lizaron otras referencias y se incluyeron 18 estudios idó-
neos. La mayoría de los estudios (72%) tuvo lugar en 
los Estados Unidos en centros de reclusión (60%) y su 
principal objetivo era mejorar las tasas de compleción 
del tratamiento dentro del establecimiento y después de 
la liberación. En los estudios que aportaban datos sobre 
las tasas de iniciación y de compleción del tratamiento 
se observaron bajos índices de éxito terapéutico en los 
centros correccionales. Las reacciones adversas y la in-
terrupción del tratamiento comunicados en los estudios 
oscilaron entre 1% y 55% (mediana de 5%) y el efecto 
adverso más frecuente fue la hepatotoxicidad. Aunque 
la coinfección por el virus de la inmunodeficiencia hu-
mana (VIH) es un factor que acelera la evolución hacia 
la enfermedad tuberculosa activa, solo la mitad de los 
estudios suministraban información al respecto. Los re-
sultados de los cuatro estudios en los cuales se evaluó la 
eficacia del IPT fueron equivalentes a los descritos en 
los entornos comunitarios. En los estudios futuros, es 
preciso realizar una evaluación completa de las tasas de 
iniciación y de compleción del IPT y de sus reacciones 
adversas, sobre todo en los países de medianos y bajos 
ingresos donde la coinfección por el virus de la hepatitis 
puede influir en forma considerable en los desenlaces y 
en los entornos donde la TB y la infección por el VIH 
son más endémicas.
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